热门资讯> 正文

Instil Bio非GAAP每股收益为-3.24美元

2025-08-13 20:37

Instil Bio press release (NASDAQ:TIL): Q2 Non-GAAP EPS of -$3.24.
As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash,

More on Instil Bio

Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
Instil Bio to begin testing antibody therapy in solid tumors
Instil Bio appoints Jamie Freedman as Chief Medical Officer

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。